STAT Cholesterol zAĸzAapplSTCOAcodetSTRZntFRMltFRMxtSTR TbmptSTRtSTRtSTR (ftSTR@tSTRtSTRtSTRLtFRMtSTR tSTRtFRM#tSTR4tFRMtFRM]tFRM@ũtFRM TbmptFRM'Tbmpl=Tbmp%TbmpTbmp@әTbmpAtFRMlTbmp{TbmpLtSTRۏMBARTbmp0TbmptTbmpTbmptSTRl0tSTR4tAIB3tFRMx+tSTRtSTRxtFRMLtSTR `Tbmp41tAIBLtAIBatAIBTaltYTaltLTaltTbmpMyTaltTbmpTbmpeTbmpdataMENU#TaltPcodemtAINtaictverHzV0NuNV/ $n Hn//./.NO $0.O$_N^NuWriteDBDataNV/B'HxCould not find appStarter.cCould not launch appStarter.cNVBmBmBmBmBmBmBmBm;|BmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmBmN^NuClearAllNV/ NOs$H?./ NO\O?/ NO\O$_N^NuGetObjectPtrNVHNOrTO/NOB'?<N,TO/NOB'?<NTO/NOB'?< NTO/NOB'?< NTO/NOB'?< NTO/NOB'?< NTO/NOB'?< NTO/NOB'?<(NTO/NOB'?<%NTO/NO<?<NTO/NO mOTf?<?<NhTO/NO\O`FJmf?<?<NJTO/NO\O`(Bg?<N4TO/NOBg?<N"TO/NOO ?-?<N TO/NOJm\Og<?<NTO/NO<?<NTO/NO<?<NTO/NO<?<NTO/NOB'?<NTO/NOB'?<NTO/NOB'?<NzTO/NOB'?<NhTO/NOO0NOrdNQ4/NOH H@;@0-XO @ b@0;N.Hb|<?<NTO/NO\O`<?< NTO/NO\O`<?< NTO/NO\O`<?< NTO/NO\O`<?< NTO/NO\O`v<?< NTO/NO\O`^<?<(NpTO/NO\O`F<?<(NXTO/NO\O`.<?<(N@TO/NO\O`<?<(N(TO/NO\O0- @ b@0;N.Hb|?</ NO\O?/ NO\O`?</ NO\O?/ NO\O`?</ NO\O?/ NO\O`?</ NO\O?/ NO\O`?</ NO\O?/ NO\O`v?</ NO\O?/ NO\O`^?<)/ NO\O?/ NO\O`F?<)/ NO\O?/ NO\O`.?<)/ NO\O?/ NO\O`?<)/ NO\O?/ NO\O?-?<NTO/NO?-?<NTO/NO<?<NTO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NTO/NO?-?<NzTO/NO?-?<NfTO/NO$H/ ?<NRTO/NO?-?<N>TO/NO?-?<N*TO/NO$H/ ?<NTO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NTO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NTO/NO?-?<NTO/NO?-?<NvTO/NO$H/ ?<NbTO/NO?-?<&NNTO/NO?-?<&N:TO/NO$H/ ?< N&TO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NTO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NTO/NO?-?<NTO/NO?-?<NTO/NO$H/ ?<NrTO/NO?-?<N^TO/NO?-?<NJTO/NO$H/ ?<N6TO/NOO$_&_N^NuMainFormInitNVB'?<NTO/NOB'?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NzTO/NO?</.NO\O?/.NON^NuCHDRiskEquivalentsFormInitNVB'?<N*TO/NOB'?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?-?<NTO/NO?</.NO\O?/.NOJmO6gATHP?<NhTO/NOPOJmgA@HP?<NJTO/NOPON^NuMajorRiskFactorsFormInit(HDL<1.03[HDL>=1.55 removes one above]NVB'?<NTO/NOB'?<NTO/NOB'?<NTO/NOB'?<NTO/NOB'?<NTO/NOB'?<NTO/NOB'?<N~TO/NOB'?<NlTO/NOB'?<NZTO/NOB'?<NHTO/NOB'?<N6TO/NO?</.NO\O?/.NOJmOHfAHP?<NTO/NOPO`\ mlAHP?<NTO/NOPO`: mnAHP?<NTO/NOPO`AHP?<NTO/NOPOJmfAHP?<NTO/NOPO`B m(lAHP?<N`TO/NOPO` mTO/NOPOJmfAlHP?<N TO/NOPO` mdlALHP?<NTO/NOPO` mnA0HP?<NTO/NOPO`\ mnAHP?<NTO/NOPO`: mnAHP?<NTO/NOPO`AHP?<NzTO/NOPO0-S@g2S@gS@g` AHP?<NJTO/NOJmPOfAHP?<N,TO/NOPO`AHP?<NTO/NOPOJmfAHP?<NTO/NOPO`AHP?<NTO/NOPO mdm<?<NTO/NO\O mm<?<NTO/NO\O` mdm~<?<NzTO/NO\O`dA HP?<N^TO/NOJmPOfAHP?<N@TO/NOPO`AHP?<N&TO/NOPOJmf:JmgAHP?<NTO/NOPO`RAHP?<NTO/NOPO`8JmgAHP?<NTO/NOPO`AHP?<NTO/NOPO mm<?<NTO/NO\OJmg mm<?<NlTO/NO\OJmfR mmH<?<NDTO/NO\O`.AHP?<N(TO/NOJmPOfAHP?<N TO/NOPO`AHP?<NTO/NOPOJmfAHP?<NTO/NOPO`AHP?<NTO/NOPO mm<?<NTO/NO\O mm<?<N|TO/NO\O`f mm^<?<N\TO/NO\O`FA^HP?<NBTO/NOAJHP?<N,TO/NOA6HP?<NTO/NOON^NuRiskCategoryFormInitN/ADesirableBorderlineHighN/ALowHighN/AOptimalNear optim.BorderlineHighVery highCHD/Equivalent< 100< 2.58>= 130>= 3.362+ Risk Factors< 130< 3.36>= 130>= 160>= 3.36>= 4.130-1 Risk Factors< 160< 4.13>= 190>= 4.91NVB'?<NTO/NOB'?< NTO/NOJmO gAHP?< NTO/NOPOJmgAHP?<NTO/NOPOJmgAHP?< NnTO/NOPO?</.NO\O?/.NOJm\Og?<?< N8TO/NO\OJmg?<?< NTO/NO\OJmg?<?<NTO/NO\OJmg?<?<NTO/NO\OJmg?<?<NTO/NO\O mm?<?< NTO/NO\OJmg$ m(lJmg?<?<NTO/NO\OJmf$ m2lJmg?<?<NVTO/NO\OJmg?<?<N:TO/NO\OJmg?<?<NTO/NO\ON^NuMetabolicSyndromeFormInit\Triglycerides >=1.69 mmol/LHDL chol M <1.03; F <1.29 mmol/LAbd. obesity M >102; F >88 cmNVB'?<pNTO/NOB'?<mNxTO/NOB'?<rNfTO/NO?<p/.NO\O?/.NO mOm<?<sN.TO/NO\O mmAHP?<rNTO/NOPO`| mmAHP?<rNTO/NOPO`Z mmA|HP?<rNTO/NOPO`8JmoAlHP?<rNTO/NOPO`AZHP?<rNTO/NOPON^NuTriglyceridesFormInit,Very HighHighBorderline highNormalN/ANV=|=nBn=|HnNON^NuAddKeyDownEventNV/ /v0.@Lg6S@gJS@gS@gXS@gS@gS@gp@^gS@gS@g` HxNO?<NOv\O`HxNO?<NOv\O`HxNO?<xNOo$H/ NO/ NOpvO`HxNO?<LNOv\O`HxNO?<NOo$H/ NO/ NOpvO`HxNO?< NOo$H/ NO/ NOpvO``HxNO?<LNOo$H/ NO/ NOpvO`:NNO?<NOvTO`$Nv`?<NOJ@TOgBm`;|v&$_N^NuMainFormDoCommandNVH8(. ˙NOrdN=H/NOHH@6/NOS(HHxNO&H/ NO!$HAHP/ NOO0 @b@0;N|2R .,<L\lAHP/ NOAHP/ NOO``AHP/ NOAHP/ NOAHP/ NOAHP/ NOAHP/ NOO(`A$HP/ NOPO` AxHP/ NOPO`AHP/ NOAHP/ NOAHP/ NOO`A HP/ NOPO`AfHP/ NOPO`AHP/ NOPO`A@HP/ NOPO`AHP/ NOAHP/ NOAHP/ NOAHP/ NOAHP/ NOAHP/ NOAHP/ NOO8`(AHP/ NOPO`AHP/ NOPO`ATHP/ NOPO`AHP/ NOPO`AHP/ NOPO`ALHP/ NOPO`AHP/ NOPO`AHP/ NOPO`APHP/ NOPO`AHP/ NOPO`tAHP/ NOPO`dA 4HP/ NOPO`TA dHP/ NOPO`DA HP/ NOPO`4A HP/ NOA THP/ NOA JHP/ NOA @HP/ NOO / /NOX/NO5 O g/ NO+XOLN^NuDrawAd Are you a chronic upcoder? That's bad. Consistent downcoder? Even worse. Don't know? Good luck! 272.2 MIXED HYPERLIPIDEMIA 401.9 HYPERTENSION NOS These and 13,000 other codes are found in STAT ICD-9 CoderSTAT CPT Coder Comprehensive CPT 2001 surgical procedure codes along with RVU values in your pocket.How do you get credit for counseling and coordination for cardiac risk? See the time criteria for each level.Learn to use the cardiovascular exam and nine other HCFA organ-specific exams. STAT E&M CoderSTAT E&M Coder: Or How I Learned to Love HCFA 1997. Download a free trial version at: www.statcoder.comAre your Level 4 and 5 services being downcoded due to 'insufficient documentation'? Learn how to put a stop to it.Get credit for the highest level of diagnostic specificity possible. Do it yourself and do it right. STAT ICD-9 Coder. www.statcoder.comMaster HCFA's Evaluation & Management (E&M) coding guidelines. Solve the comp- liance and revenue problem.Compliance Risk Factors: High levels of service Low knowledge of coding rules. Try STAT E&M CoderSTAT E&M Coder The gold standard recommended by coding professionals. Accept no substitutes!Navigate the ACC/AHA or ACP Guidelines for Perioperative Cardiovascular Evaluation. STAT Cardiac ClearanceFREE SOFTWARE! The latest pediatric growth charts calculated on your Palm. STAT GrowthCharts'This software paid for itself the very first day of use. I'm coding much better' STAT E&M CoderThe full Adult Treatment Panel III Report and more information are available at: http://www.nhlbi.nih.govFree demo's of all our coding software are available via direct download from our website www.statcoder.comBeam this software to a colleague via the Menu button (tap Options). It only takes a few seconds!'This coding problem is costing me a lot of money!' Try STAT E&M Coder free of charge. www.statcoder.com'This has been a great program for me. I was seriously under- coding due to my fears of being audited.' STAT E&M CoderFree demo period for all software. Available for download at www.statcoder.comAlso available: STAT Cardiac Clearance STAT GrowthCharts www.statcoder.comDownload updates of this and other software. www.statcoder.comSTAT E&M Coder STAT ICD-9 Coder STAT CPT Coder www.statcoder.comSponsor STAT Cholesterol and feature your product in this space. Contact info@statcoder.com'This is the best program I have ever seen that helps the physician decide which billing code to use for a patient visit' NVH0vxBmBmBmBmBmBmBmBm?<NTO/NOJ@XOf?<NTO/NOJ@XOg?<NTO/NO;@XO`vJmg?<N۴$HTO` ?<Nۦ$HTOJmg?<N۔&HTO` ?<Nۆ&HTO?<NzTO/NOXO @ bZ@0;N8Tl4v`4Jmg;|`;|Bm`Jmg;|`;|Bm`JmgBm`BmBm`Jmg;|`;|Jmg ;|`Bm`Jmg;|`;|Jmg ;|`Bm`Jmg;|`;|;|`nJmg;| `;| ;|`RJmg;| `;| ;|`6Jmg;| `;|;|`Jmg;| `;|;|?<NTO/NOXO @ b@0;N6Nf|x`Jmg ;|`;|`JmgBm`;|`Jmg ;|`Bm`Jmg;|`|;|`tJmg;|`f;|`^Jmg;|`P;|`HJmg;|`:;|`2Jmg;|`$;|`Jmg;|`;|`;|cJmg/ NOXO @b@0;N Zv`Bm`?<NظTO/NOXO @ bH@0;N""**22::v`$;|`;|`;|` ;|`Bm;|`"?<NNTO/NOXO @ bH@0;N""**22::v`$;|`;|`;|` ;|`Bm;|`?<NTO/NOXO @ bJ@0;N""**22::v`&;| `;|`;|`;|`;|;|`L?<NxTO/NOXO @ bJ@0;N""**22::v`&;| `;|`;|`;|`;|;|`/ NOXO @b@0;N \v`Bm`?<NTO/NOXO @ bJ@0;N""**22::v`&;|`;|`;|`;|`;|;|`@?<NlTO/NOXO @ bJ@0;N""**22::v`&;|`;|`;|`;|`;|;|`?<NTO/NOXO @ bJ@0;N""**22::v`&;| `;|`;|`;|`;|;|`h?<NՖTO/NOXO @ bJ@0;N""**22::v`&;| `;| `;|`;|`;|;|/ NOXO @b@0;N &8Ndx`hJmg;|`Z;|`RJmgBm`FBm`@Jmg;|`2;|`*Jmg;|`;|`Jmg;|`;|?<NԜTO/NOJ@XOg?<NԄTO/NOXO @ b@0;N00FF\\rrv`rJmg;|`d;| `\Jmg;|`N;|`FJmg;|`8;|`0Jmg;|`";|`Jmg;|` ;|`Bm/ NOXO @bP@0;N ,,::v`4;|;|<`&Bm;|2`;|;|(` ;|;|'/ NOXO @b@0;N(:NNdx`fJmg;|`X;|`PJmgBm`DBm`>JmgBm`2;|`*Jmg;|`;|`Jmg;|`;|?<NTO/NOJ@XOf?<NTO/NOXO @b>@0;N (@Zxv`"JmgBm`Bm` JmgBm`;|`Jmg ;|`;|`Jmg;|`;|;|`Jmg;|`;|;|`?<NTO/NOXO @b@0;N "8Ndv`hJmgBm`\Bm`VJmg;|`H;|`@Jmg;|`2;|`*Jmg;|`;|`Jmg;|`;|?<NvTO/NOXO @b@0;N $6J`x`dJmgBm`X;|`PJmgBm`DBm`>Jmg;|`0Bm`*Jmg;|`;|`Jmg;|`;|?<&NTO/NOXO @b@0;N $6J`x`dJmgBm`X;|`PJmgBm`DBm`>Jmg;|`0Bm`*Jmg;|`;|`Jmg;|`;|;m0-mmmm;@JmgJCgJmlAHP?<NTO/NOPO` mo"AHP?<NTO/NO;|PO`h0- @bD@0;N$@\x <XtAHP?<NώTO/NOPO`AHP?<NrTO/NOPO`AhHP?<NVTO/NOPO`APHP?<N:TO/NOPO`A8HP?<NTO/NOPO`A HP?<NTO/NOPO`AHP?<NTO/NOPO`jAHP?<NTO/NOPO`NAHP?<NήTO/NOPO`2AHP?<NΒTO/NOPO`AHP?<NvTO/NOPO`AHP?<NZTO/NOPO`AxHP?<N>TO/NO;|PO`AZHP?<NTO/NO;|PO`AZv:VxA(HP?<NTO/NOPO`AHP?<N̮TO/NOPO`AHP?<N̒TO/NOPO`AHP?<NvTO/NOPO`AHP?<NZTO/NOPO`AHP?<N>TO/NOPO`jAHP?<N"TO/NOPO`NAHP?<NTO/NOPO`2AhHP?<NTO/NOPO`APHP?<NTO/NOPO`A8HP?<N˲TO/NOPO`A HP?<N˖TO/NO;|PO`AHP?<NtTO/NO;|PO`AHP?<NRTO/NO;|PO`xAHP?<N2TO/NO;|PO`XAHP?<NTO/NO;|PO`8AHP?<NTO/NO;|PO`AtHP?<NTO/NOPOJmf?<NʸTO/NOXO @b<@0;N2 $,;|c`;|`;|`;|`;|?<NdTO/NOXOS@gS@gS@gS@g"`;|`;|`;|`;|`?<NTO/NOXO @b<@0;N2 $,;|c`;|`;|`;|`;|?<NTO/NOXOS@gS@gS@gS@g`;|`;|`;|`;|?<NɀTO/NO;@XOgA HP?<NbTO/NOPO?<NPTO/NO;@?<NHP?<%NXTO/NOPO`fA (HP?<%N>TO/NOPO`LA HP?<%N$TO/NOPO`2A HP?<%N TO/NOPO`A HP?<%NTO/NOPOJmfJDg mlA HP?<%NTO/NOPO` mcfA HP?<%NŞTO/NOPO` moA |HP?<%NzTO/NOPO`0-T@ @b\@0;N(D`|$@\x6A $HP?<%NTO/NOPO`&A HP?<%NTO/NOPO` AHP?<%NTO/NOPO`AHP?<%NTO/NOPO`AHP?<%NĮTO/NOPO`AHP?<%NĒTO/NOPO`AHP?<%NvTO/NOPO`~A|HP?<%NZTO/NOPO`bAdHP?<%N>TO/NOPO`FALHP?<%N"TO/NOPO`*A4HP?<%NTO/NOPO`AHP?<%NTO/NOPO`AHP?<%NTO/NOPO`AHP?<%NòTO/NOPO`AHP?<%NÖTO/NOPO`AHP?<%NzTO/NOPO`AHP?<%N^TO/NOPO`fAHP?<%NDTO/NOPO`LAxHP?<%N*TO/NOPO`2AbHP?<%NTO/NOPO`ALHP?<%NTO/NOPOJmgp?<NTO/NOXO @ bV@0;NJ~NAHP?<"NœTO/NOAHP?<#N†TO/NOO`AHP?<"NhTO/NOAHP?<#NRTO/NOO`AHP?<"N4TO/NOAHP?<#NTO/NOO`AtHP?<"NTO/NOAbHP?<#NTO/NOO`fAHHP?<"NTO/NOA6HP?<#NTO/NOO`2AHP?<"NTO/NOA HP?<#NTO/NOO`AHP?<"NdTO/NOAHP?<#NNTO/NOO`AHP?<"N0TO/NOAHP?<#NTO/NOO`AHP?<"NTO/NOAHP?<#NTO/NOO`bAnHP?<"NTO/NOA\HP?<#NTO/NOO`0ADHP?<"NTO/NOA2HP?<#NTO/NOOJmfp?<NfTO/NOXO @ bV@0;NJ~NAHP?<"N&TO/NOAHP?<#NTO/NOO`AHP?<"NTO/NOAHP?<#NTO/NOO`AHP?<"NTO/NOArHP?<#NTO/NOO`AXHP?<"NTO/NOAFHP?<#NtTO/NOO`fA,HP?<"NVTO/NOAHP?<#N@TO/NOO`2AHP?<"N"TO/NOAHP?<#N TO/NOO`AHP?<"NTO/NOAHP?<#NTO/NOO`AHP?<"NTO/NOAHP?<#NTO/NOO`A|HP?<"NTO/NOAjHP?<#NpTO/NOO`bARHP?<"NTTO/NOA@HP?<#N>TO/NOO`0A(HP?<"N"TO/NOAHP?<#N TO/NOO?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<&NTO/NO;@?<NlTO/NO;@?<NXTO/NO;@?<NDTO/NO;@?<N0TO/NO;@O,L 8N^NuUpdateScore <1%30+1%1%1%1%1%2%2%3%4%5%6%8%10%12%16%20%25%30+err<1%30+1%1%1%1%2%2%3%4%5%6%8%11%14%17%22%27%30%errCHD2%N/A53+2%3%3%4%5%7%8%10%13%16%20%25%31%37%45%53+err1%N/A27+1%2%2%2%3%3%4%4%5%6%7%8%10%11%13%15%18%20%24%27+errAvg.Low 3% 2% 5% 3% 7% 4%11% 4%14% 6%16% 7%21% 9%25%11%30%14%N/AN/AAvg.Low<1%<1% 1%<1% 2% 2% 5% 3% 8% 5%12% 7%12% 8%13% 8%14% 8%N/AN/ANV?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@JmOfJmfJmfJmf JmfJmg;|N^NuUpdateCHDRiskNV/v?<NDTO/NO;@?<N0TO/NO;@?<NTO/NO;@?<NTO/NO;@?<NTO/NO;@6-mmmmm mOg Cm;|`;|&N^NuUpdateMajorRiskNVBnA-H?< NTO/NO;@?< NlTO/NO;@?<NXTO/NO;@?<NDTO/NO;@?<N0TO/NO;@N^NuUpdateMetabolic NVH0&nv0@ g[@g:_@gW@gU@g`0+@g0_@gY@g&S@g"U@gS@g@gU@g@g`v`0- @ bf@0;N\ ,8DPPPP?<NOTO`^?<NOTO`R?<NOTO`F?<lNOTO`:?<@NOTO`.?<@NOTO`"HxNO?<NOo$H/ NO/ NOpOv`D?<NOvTO`6?<N̰vTO`(?<NOvTO`NNOs/NB?<NOv\ONۈ`0+@ @bT@0;NHPHH ?<NTO/NOXO??<NpTO/NO\O/?<N\TO/NOvPO`?<NDTO/NOXO??<N0TO/NO\O/?<NTO/NOvPO`?<NTO/NOXO??<NTO/NO\O/?<NTO/NOvPO`z?<NTO/NOXO??<NTO/NO\O/?<NTO/NOvPO`?< `NOvTO`z?< (NOvTO`l?<NOvTO`^?<NOvTO`P?<N:vTO`B?+NdTO`8NOs$H/ N/ NOq?<p/ NO\O?/ NO\O// NǶvOL N^NuTriglyceridesFormHandleEventNVH0&n Sf6+?NOo$H/ NOt\O0@g @g(@,g0@g8@dg@@dgH`RHz/ NOPO`DHz/ NOPO`6Hz/ NOPO`(Hz/ NOPO`Hz/ NOPO` Hz`/ NOPOp`pL N^NuAppHandleEventNVHxHnNOHnNOJO f0HnHnHxNOJO fHnNJXOf HnNOXO nfN^NuAppEventLoopNV=|r<HnHnBg/140 mg/dL 10 Year CHD Risk - risk of developing one of the following: angina pectoris, myocardial infarction, or coronary disease death over the course of 10 years. Avg. Risk - 10 year absolute risk for persons of the same age and sex for average total CHD Low Risk - 10 year absolute risk for persons with a low risk profile (optimal BP, chol 160-199, HDL >=45 for men >=55 for women, nonsmoking, nondiabetic). Some Caveats: This data applies only to persons without known heart disease. The Framingham Heart Study risk algorithm encompasses only coronary heart disease and not other heart and vascular diseases. The Framingham Heart Study is almost all Caucasian. The Framingham risk algorithm may not fit other populations quite as well. Events in some of the sex-age groups are small so the estimates of risk in these groups may lack precision. 10 year risk scores may not adequately reflect the lifetime CHD risk of young adults which is one in two for men and one in three for women. A single risk factor may confer a high risk in the long run even if the 10 year CHD risk does not appear to be high. 10 year CHD risks are high in older persons which may over-identify candidates for aggressive interventions. Relative risk (risk in comparison with low risk individuals) may be more useful than absolute risk in the elderly. The score derived from this tool should not be used in place of a medical examination.Source: NHLBI's Framingham CHD Risk Prediction Score Sheets Please refer to Wilson et al in the references section for further details about the methods used in the studies.M 4 NR ^ x|  z$6H\r $>Zp8  ,@Tt   6 V j ~   0       * B X n   STAT Cholesterol 1.0 ) Years y Years20-3435-3940-4445-4950-5455-5960-6465-6970-7475-79.- mg/dL.(Bmg/dL<160160-199200-239240-279280+<- mg/dL<(Mmg/dL60+50-5945-4940-4435-39< 35H% SBPX- mg/dLR$BSBP< 120120-129130-139140-159>=160Y(7mg/dL< 150150-199200-499>=500l)@@H.4 Smoke Age.Chol<HDLDBPJ[LDL]IM I\ DetailsJ- mg/dLH(Bmg/dL<100100-129130-159160-189>=190I@MI Risk Male  FemaleX[Trig]{.' [DM] Menul2P.(Bmmol/L<=4.134.14-5.165.17-6.196.20-7.23>=7.24<(Mmmol/L1.55+1.29-1.541.16-1.281.03-1.150.90-1.02<0.90.2 Hmmol/L<2 Hmmol/L l)@@ l)l@@ l)@@ l)@@ l)@@STAT ICD-9 CoderSTAT CPT Coder Beam this program!Sponsor this software!i AInfoLKAvg.\ H U Treated HTNl)@@@uKIdealSTAT E&M CoderPalm Clinical ProductivityH(Bmmol/L<2.582.58-3.353.36-4.124.13-4.91>4.91X(7mmol/L< 1.691.69-2652.66-5.64>5.64J2 Hmmol/LX2 Hmmol/LI<V x' [DBP] &!s/"A Avg.#M Low$kAAll CHD%mM &~!B[DBP]<8080-8485-8990-99>=100'l\ Clear(l)@@@)www.statcoder.comЈI  8< H bf  P 2Hd ~0F`zj  2Ln  $ 8 N x  : V Z v z      STAT Cholesterol Beta 3 ) Years!"y Years20-3435-3940-4445-4950-5455-5960-6465-6970-7475-79.- mg/dL/(Bmg/dL<160160-199200-239240-279280+<- mg/dL=(7mg/dL60+50-5940-49< 40Z! mmX- mg/dL^$Bmm< 120120-129130-139140-159>=160Y(7mg/dL< 150150-199200-499>=500n)@@K.. Smok Age.Chol<HDLMBPJ[LDL]MK L\ DetailsJ- mg/dLI(Bmg/dL<100100-129130-159160-189>=190L?MI risk Male  FemaleX[Trig]y.' [DM] Menul2P/(Bmmol/L<=4.134.14-5.165.17-6.196.20-7.23>=7.24=(7mmol/L1.55+1.29-1.541.03-1.28< 1.03/2 Hmmol/L=2 Hmmol/Ln)@@n)L@@n)@@n)@@l)x@@atorvastatin calciumsimvastatinpravastatin sodiumcerivastatin sodiumi AInfoLKAvg.\ NextK M Treated BP^K AuKIdealK APalm Clinical ProductivityI(Bmg/dL<2.582.58-3.353.36-4.124.13-4.91>4.91Y(7mg/dL< 1.691.69-2652.66-5.64>5.64K2 Hmmol/LY2 Hmmol/LK<S! mm A avg M low {/ k?All CHD lM lowThe Ventura Heart Institute's mission is to provide patients the optimal and cost effective early detection evaluations, cardiovascular risk assessments, tailored prevention strategies to reduce the risk of have the first or subsequent cardiovascular event. The Ventura Heart Institute opened in 1987 and has screened thousands of individuals for evidence of heart disease, provided heart disease education programs to the public as well as high level professional education programs to physicians and health care providers nationally as well as locally. The Institute has also participated in many research projects that have expanded the drug options to care for many high risk heart patients with elevated cholesterol, high blood pressure, heart failure, irregular heart beats, and those with recent balloon dilation of tight heart blood vessels. However, the Ventura Heart Institute believes that the best treatment of cardiovascular disease is in prevention of future or recurrent events. Early detection programs by risk factor assessment, stress electrocardiographic and stress echocardiographic testing are available. The Ventura Heart Institute is a member organization of several professional bodies that address similar issues. Amongst these are the Cardiovascular Disease Prevention Coalition (funded by the California Department of Health Services) which seeks to provide cardiovascular health programs for the underserved populations in California as well as address broad legislative issues such as tobacco legislation and public health. The Western Lipid Association is a group of academic and private physicians in the Western United States developing programs to optimize the care of patients with abnormal blood fats such as cholesterol elevation. The Healthcare Forum at UCLA is a group of academic, private, and industry concerns operating under the aegis of the UCLA Anderson School of Business and the UCLA School of Public Health to assess and evaluate trends in healthcare in this volatile managed care marketplace. The Vascular Biology Working Group is a coalition of academic and private institutions assessing cardiovascular research and translating significant findings into the practice of medicine. Another major focus of the Ventura Heart Institute is the application of information technology to optimize the management of diseases. The best care for many high risk patient groups has been outlined by several expert panels, yet the ability of providers to deliver that care has many barriers. The pragmatic harnessing of constantly evolving information technology to ensure the best quality and outcome is a cornerstone of surmounting many of these barriers.}} ? ?7oۻ{Eo%o6ymt%z) v+ z  {~ /$ w@m6 t@wx} OC-_H kk F7? [Ѐ@ {~P"^Hk BB/@*+_IR$-?؈D OP_ a O􄾓-m= w `[ J ?,Nl>@@Z_.?H"(E&??TDO??"k?7_?+Y/TUD7?RA* wW @/_/$!Hok mb@by  @XiR?(X4  Identify metabolic syndrome and treat, if present, after 3 months of TLC. Clinical Identification of the Metabolic Syndrome . Any 3 of the Following: Abdominal obesity* Waist circumference. - Men >102 cm (>40 in); - Women >88 cm (>35 in) Triglycerides >150 mg/dL HDL cholesterol - Men <40 mg/dL - Women <50 mg/dL Blood pressure >130/>85 mmHg Fasting glucose >110 mg/dL * Overweight and obesity are associated with insulin resistance and the metabolic syndrome. However, the presence of abdominal obesity is more highly correlated with the metabolic risk factors than is an elevated body mass index (BMI). Therefore, the simple measure of waist circumference is recommended to identify the body weight component of the metabolic syndrome. Some male patients can develop multiple metabolic risk factors when the waist circumference is only marginally increased, e.g., 94-102 cm (37-39 in). Such patients may have a strong genetic contribution to insulin resistance. They should benefit from changes in life habits, similarly to men with categorical increases in waist circumference. Treatment of the metabolic syndrome Treat underlying causes (overweight/obesity and physical inactivity): -Intensify weight management -Increase physical activity Treat lipid and non-lipid risk factors if they persist despite these lifestyle therapies: -Treat hypertension -Use aspirin for CHD patients to reduce prothrombotic state -Treat elevated triglycerides and/or low HDLThis educational program is based on Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Clinicians should have some familiarity with the ATP III Guidelines prior to using this tool.. The ATP III Executive Summary is available online at http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm Enter the relevant clinical information on each screen and view results and reccomendations according to the ATP guidelines. Tap the arrow buttons to move to the next screen. Often, boxes will be already be checked based on information you have previously entered. Tapping the Details button will reveal information about that section taken directly from the published guidelines. Metric units (i.e. mmol/L) can be used by selecting MENU -> Options. This program may be beamed directly to another Palm OS handheld by tapping Menu -> Options. If you wish to demonstrate this program on a PC, a special version of the Palm Emulator is available for download with this software pre-installed. Visit the www.statcoder.com site. This program is currently beta testing and may contain errors. Please download updated versions, often, from www.statcoder.com. Comments regarding this software are welcome via email. Pharmaceutical company inquiries regarding sponsorship of this application are also welcome. Andre S. Chen, MD, MBA www.statcoder.com achen@statcoder.com Treatment of elevated triglycerides (=150 mg/dL) Primary aim of therapy is to reach LDL goal. Intensify weight management. Increase physical activity. If triglycerides are =200 mg/dL after LDL goal is reached, set secondary goal for non-HDL cholesterol (total . HDL) 30 mg/dL higher than LDL goal. If triglycerides 200-499 mg/dL after LDL goal is reached, consider adding drug if needed to reach non-HDL goal: -intensify therapy with LDL-lowering drug, or add nicotinic acid or fibrate to further lower VLDL. If triglycerides =500 mg/dL, first lower triglycerides to prevent pancreatitis: -very low-fat diet (=15% of calories from fat) -weight management and physical activity -fibrate or nicotinic acid -when triglycerides <500 mg/dL, turn to LDL-lowering therapy. Treatment of low HDL cholesterol (<40 mg/dL) First reach LDL goal, then: Intensify weight management and increase physical activity. If triglycerides 200-499 mg/dL, achieve non-HDL goal. If triglycerides <200 mg/dL (isolated low HDL) in CHD or CHD equivalent, consider nicotinic acid or fibrate.STAT E&M Coder is an interactive Evaluation and Management template for your Palm. As you dictate your note, tap the relevant elements that you are documenting and let the program do all the counting as well as navigate the complex E&M coding algorithms used by HCFA and insurance companies. For example, there are 8 possible History of Present Illness (HPI) elements, four of which must be documented in order to document above a Level II New Patient Visit. Alternatively, the status of three chronic conditions can be substituted. STAT E&M Coder counts the History, Exam, and Medical Decisionmaking elements for you and navigates the different algorithms for 17 different E&M types. Included are the individual time criteria for Counseling and Coordination. STAT E&M Coder is available for free trial download at www.statcoder.com. Try it and, finally, fix your compliance problem from overcoding and/or lost revenue problem from undercoding. Registration costs only $75.All 15,000 ICD-9-CM Diagnosis Codes in Your Pocket! STAT ICD-9 Coder presents the comprehensive list of ICD-9 codes with descriptions, in outline format in the most compact form ever available. Start from broad organ system categories and rapidly narrow down to achieve the highest level of specificity in just a few seconds. Unlike partial lists which contain a lot of three digit codes or "NOS" codes which often aren't reimbursable, this software presents every ICD-9 code. Using the efficient TealInfo database format, this software uses a maximum of 600K of your Palm memory. You may install only the code sections that you need. Code it yourself. Code it right. Download the demo from www.statcoder.com. Purchase and download the working version for only $29. Registration of TealInfo is not included.All references are available on the internet. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary http://www.nhlbi.nih.gov/guidelines/cholesterol/atp_iii.htm Estimating Coronary Heart Disease (CHD) Risk Using Framingham Heart Study Prediction Score Sheets (http://rover.nhlbi.nih.gov/about/framingham/riskabs.htm) Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847. Primary Prevention of Coronary Heart Disease: Guidance From Framingham - A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction (http://www.americanheart.org/Scientific/statements/1998/059801.html) STAT Cholesterol 2001 Austin Physician Productivity www.statcoder.com The user interface forms and elements contained in this software are trademarks of Austin Physician Productivity, LLC. AUSTIN PHYSICIAN PRODUCTIVITY HEREBY DISCLAIMS ALL WARRANTIES AND CONDITIONS WITH REGARD TO THE SOFTWARE, INCLUDING ALL IMPLIED WARRANTIES AND CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT. IN NO EVENT SHALL AUSTIN PHYSICIAN PRODUCTIVITY BE LIABLE FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM FINES, PENALTIES, LOSS OF USE, DATA, OR REVENUE , WHETHER IN AN ACTION OF CONTRACT, NEGLIGENCE OR OTHER TORTIOUS ACTION, ARISING OUT OF OR IN CONNECTION WITH THE USE OR PERFORMANCE OF THIS APPLICATION.  ,DZ.D\Risk Categoryi Menu^Chol+Treat at\ /<P Lifestyle Changes/KP Drug Therapyk\ \ Details LDL goalq. q. V ,+ =Initiate:l2Pq+. ^,LDL^HDL,++ KConsider:/KP Drug OptionalDetermine risk category: Establish LDL goal of therapy Determine need for therapeutic lifestyle changes (TLC) Determine level for drug consideration * Some authorities recommend use of LDL-lowering drugs in this category if an LDL cholesterol <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ** Almost all people with 0-1 risk factor have a 10-year risk <10%, thus 10-year risk assessment in people with 0-1 risk factor is not necessary. Comprehensive Surgical Procedure Codes and RVU's For Your Pocket Includes all CPT 2001 surgical procedure codes with medium length descriptions. It displays RVU values for each procedure and is categorized by organ system. Runs on any Palm OS PDA using the TealInfo shareware database format. Using the efficient TealInfo database format, this software uses a maximum of 500K of your Palm memory. You may install only the code sections that you need. Code it yourself. Code it right. Download the demo from www.statcoder.com. Purchase and download the working version for only $50. Registration of TealInfo is not included.  6j<Major Risk Factorsi Menu6 Smoking 6 HDL <40\ . Family history of premature CHD:1st degree; M <55 y.o.; F <65 y.ok\ l2PDS HTN (>140/90)\ DetailsD ] Age (M>45; F>55)F [HDL>=60 removes one above]Determine presence of major risk factors (other than LDL): Major Risk Factors (Exclusive of LDL Cholesterol) That Modify LDL Goals Cigarette smoking Hypertension (BP >140/90 mmHg or on antihypertensive medication) Low HDL cholesterol (<40 mg/dL)* Family history of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years) Age (men >45 years; women >55 years) * HDL cholesterol >60 mg/dL counts as a "negatie" risk factor; its presence removes one risk factor from the total count. Note: in ATP III, diabetes is regarded as a CHD risk equivalent. H^"<Metabolic Syndrome i  Menu  Abd. obesity M >40; F >35 inches ' Triglycerides >=150 mg/dL \ 3 HDL chol M <40; F <50 mg/dL? Blood pressure >=130/85 mmHgk\ K Fasting glucose >=110 mg/dL\ DetailsAny three:l2P܀ :P$CHD Risk Equivalentsi MenuA Clinical CHD Symptomatic carotid artery dis.\ (~ Peripheral arterial disease4 Abdominal aortic aneurysmk\ @7 DiabetesL^ 10 year risk >20%\ Detailsl2P@ 2NvCardiac Risk Demo 1.1ASelect sample sponsor display:B 2< LipitorC K< ZocorDZ2< PravacholEZK< BaycolGThis demo will expire in Hdays.Il JsPlease contact achen@statcoder.com for licensing information.Kd2001 Austin Physician Productivity2  twww.statcoder.com ]STAT Growth Charts STAT Cardiac Risk Implement the Framingham Heart Study Prediction Scores hCalculate growth percentiles using the new CDC Growth Charts including new BMI-for-age charts. !9( OK "1STAT Cardiac Clearance #<Navigate the ACC/AHA or ACP Guide- lines for Perioperative Cardiovascular Evaluation(?φpc@Ya @A1c1sfI$pd6pJR" f>0^c&ydPg q10b81t|;5{n`U׻WP !?euu{nPt{|vp:?UkUD+D.0kE "JE(@U!)BkC .D®U()B*"hkD"J)(@UE+9.0kU2 t`xwww.statcoder.com?STAT ICD-9 CoderSTAT E&M CoderdSTAT CPT Coder A unique tool that makes evaluation & management coding and docu- mentation work for clinicians.9( OKJThe most compact version of the complete ICD-9 diagnosis codespPortable and comprehensive CPT and RVU surgical coding reference(9>1 81m3< la0l1[a`><<[066 1m3; 90A8I/F";̋ "DI2X2 I>TPUR*0]S;?;^P0w"R&P]DI"R"0A:FD:0k Uk <9˿Z׽/FVnx;)Lx7f"{ށp 3wcp} 0`xа~` rqd`9 *p0p< ` 808 gxpG 'z  8}0 ;'^g A0 gA `8 ai@ A?̀`)`?nj ~8 x~?(?1`;$Dd /l92,cib?`:mIRͭlR1y^JB@*"?l;98ώ@?@FIADB(?A I(FD@Q:Zbﱎ!)Jm^JR^ :bͺI ?(?1`;$Dd /l92,cib?`:mIRͭlR1y^JB@*"?l;98ώ@?@FIADB(?A I(FD@Q:Zbﱎ!)Jm^JR^ :bͺI ?( ><|C~cÀs#` 3  x7>la4>?}cu lc9p03pfw1`x tg3g{398`af3<?cpܽv`a=` \fpƀ(|~{=fx<;q839 l 0FdzElevated Triglyceridesmin Menuo $Classification:pl2Pq\ rG$F sG;7 ITreatmenttk\ w\ Details){@ w#?m? ?5?p1?0?e=??i2 ?  O 0:%~!?;?1p0<?! -% #]?=@)xx&?vZ e[ Y ) 8? &?`5V ? 0 @@`A?@@P@? e@(܇`Ev>? B?`@H? `EY[PEZ0f?Initiate therapeutic lifestyle changes (TLC) if LDL is above goal. TLC Features TLC Diet: - Saturated fat <7% of calories, cholesterol <200 mg/day - Consider increased viscous (soluble) fiber (10-25 g/day) and plant stanols/sterols (2g/day) as therapeutic options to enhance LDL lowering Weight management Increased physical activity\MD d>`!H/ LMNOPQR &3InformationInstructionsReferencesDedicationAboutCoding SoftwareClinical SoftwareDisclaimerOptionsRestartBeam ProgramChoose Chol. Units(3 4x'?93Jx98㈉A3|?əHh~h><I81?_8xo<'9_(3 4x'?93Jx98㈉A3|?əHh~h><I81?_8xo<'9_(3 4x'?93Jx98㈉A3|?əHh~h><I81?_8xo<'9_(!cc}3wsc99d>?{s@?? #c999??COMING SOON - Pharmaceutical company sponsorship of this unique clinical tool If your company is interested in sponsoring this free clinical software, featuring cardiovascular health products in the advertising space, please inquire via email at our website.Identify presence of clinical atherosclerotic disease that confers high risk for coronary heart disease (CHD) events (CHD risk equivalent): Clinical CHD Symptomatic carotid artery disease Peripheral arterial disease Abdominal aortic aneurysm    **  >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>2x \|About This Softwarez+STAT Cholesterol{S 2001 www.statcoder.com}:( OKYou can beam this program directly to another Palm OS handheld using the infrared port. Tap the Menu button, then Options, then Beam Program. It only takes a few seconds to share this with an interested colleague.Consider adding drug therapy if LDL exceeds levels shown in Step 5 table: Consider drug simultaneously with TLC for CHD and CHD equivalents Consider adding drug to TLC after 3 months for other risk categories2LV^vN OKO This free application is developed in memory of Martha W. Coleman, M.D.Treat elevated triglycerides. ATP III Classification of Serum Triglycerides (mg/dL) < 150 Normal 150-199 Borderline high 200-499 High =500 Very high( x|xcyyyyyy3p@ x|xcyyyyyy3p@ ?π< | |0|0|2|2|&|A~?<x0System IncompatibleSystem Version 2.0 or greater is required to run this application.OKWarningThis is an old version. Please download an update from www.statcoder.com soonOKWarning!This is a demonstration program and is not intended for clinical use . OKC?π< |@ @0@2@&A~?<`@xCholesterol UnitsUse mmol/L cholesterol units? (must restart)YesNo6??6??6|<  <|"@((OptionsAbout Starter AppConfirmationYes!OK0x ?<CholesterolMain1.0